Supplemental material
Drug Delivery
Volume 24, 2017 - Issue 1
Related Research Data
Resistance to HIV Infection
Source:
Springer Science and Business Media LLC
HIV entry inhibitors: mechanisms of action and resistance pathways
Source:
Oxford University Press (OUP)
Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates
Source:
Mary Ann Liebert Inc
Liposomes for HIV prophylaxis
Source:
Elsevier BV
CD4 Binding Site Antibodies Inhibit Human Immunodeficiency Virus gp120 Envelope Glycoprotein Interaction with CCR5
Source:
American Society for Microbiology
Protein/peptide-based anti-HIV therapies
Source:
Wiley
A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.
Source:
Proceedings of the National Academy of Sciences
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
Source:
Proceedings of the National Academy of Sciences
In situ stabilized AgNPs and (Cu-Cur)CD dispersed gel, a topical contraceptive antiretroviral (ARV) microbicide
Source:
Royal Society of Chemistry (RSC)
Dendrimer Delivery of Oligonucleotides
Source:
Informa UK Limited
The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs Is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor
Source:
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti‐HIV microbicide
Source:
Wiley
Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes
Source:
American Society for Microbiology
Nanotechnology in vaccine delivery.
Source:
Elsevier BV
(Copper-curcumin) β-cyclodextrin vaginal gel: delivering a novel metal-herbal approach for the development of topical contraception prophylaxis.
Source:
Elsevier BV
Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket
Source:
Elsevier BV
Albumin stabilized silver nanoparticles–clotrimazole β-cyclodextrin hybrid nanocomposite for enriched anti-fungal activity in normal and drug resistant Candida cells
Source:
Royal Society of Chemistry (RSC)
Nanoparticle-based vaginal drug delivery systems for HIV prevention.
Source:
Informa Healthcare
Preparation and characterization of solid lipid nanoparticles containing silibinin.
Source:
Informa UK Limited
HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion.
Source:
Elsevier Inc.
Core structure of GP41 from the HIV envelope glycoprotein
Source:
Elsevier BV
Lipid composition has significant effect on targeted drug delivery properties of NGR-modified liposomes.
Source:
Informa UK Limited
Structural basis for membrane fusion by enveloped viruses
Source:
Informa UK Limited
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
Source:
American Society of Hematology
Rational Design of Targeted Next-Generation Carriers for Drug and Vaccine Delivery
Source:
Annual Reviews
Cationic liposomes are possible drug-delivery systems for HIV fusion inhibitor sifuvirtide
Source:
Royal Society of Chemistry (RSC)
A novel and efficient asymmetric synthesis of anti-HIV drug maraviroc
Source:
Informa UK Limited
CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor.
Source:
Elsevier BV
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
Source:
Oxford University Press (OUP)
Atomic structure of the ectodomain from HIV-1 gp41
Source:
Springer Science and Business Media LLC
2008 Recommendations of the International AIDS Society–USA Panel
Source:
American Medical Association (AMA)
A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection
Source:
Rockefeller University Press
Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
Source:
Elsevier BV
cocktail therapeutic strategy for antiviral therapy
Source:
Ovid Technologies (Wolters Kluwer Health)
Protein design of an HIV-1 entry inhibitor
Source:
American Association for the Advancement of Science (AAAS)
Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses
Source:
American Society for Microbiology
Evaluation of -2 RANTES Vaginal Microbicide Formulations in a Nonhuman Primate Simian/Human Immunodeficiency Virus (SHIV) Challenge Model
Source:
Mary Ann Liebert Inc
Capture of an early fusion-active conformation of HIV-1 gp41
Source:
Springer Science and Business Media LLC
In-vitro anti-viral screening and cytotoxicity evaluation of copper-curcumin complex.
Source:
Informa UK Limited
Resistance to enfuvirtide, the first HIV fusion inhibitor
Source:
Oxford University Press (OUP)
Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1
Source:
Elsevier BV
Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro
Source:
American Society for Microbiology
Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents.
Source:
Elsevier BV
Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer
Source:
AIP Publishing
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites
Source:
Informa Healthcare
Detection of functional galactosylceramide (GalCer) receptors on CD4-negative HIV-1 target cells
Source:
Springer Science and Business Media LLC
Nef Does Not Affect the Efficiency of Human Immunodeficiency Virus Type 1 Fusion with Target Cells
Source:
American Society for Microbiology
Vaginal microbicides and their delivery platforms.
Source:
Informa Healthcare
Dendrimers as potential therapeutic tools in HIV inhibition.
Source:
MDPI AG
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.
Source:
Rockefeller University Press
Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides
Source:
American Society for Microbiology
Development and characterization of niosomal gel for topical delivery of benzoyl peroxide
Source:
Informa UK Limited
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Source:
Springer Science and Business Media LLC
Molecular architecture of native HIV-1 gp120 trimers.
Source:
Springer Science and Business Media LLC
Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections
Source:
Informa UK Limited
Interaction of silver nanoparticles with HIV-1
Source:
Springer Science and Business Media LLC
HIV-1 entry inhibitors: recent development and clinical use.
Source:
Elsevier BV
pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs.
Source:
Springer Science and Business Media LLC
Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T-20 Are Potently Synergistic in Blocking Virus-Cell and Cell-Cell Fusion
Source:
Oxford University Press (OUP)
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
Source:
Proceedings of the National Academy of Sciences
Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Source:
Bentham Science Publishers Ltd.
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Source:
Proceedings of the National Academy of Sciences
A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
Source:
Springer Science and Business Media LLC
Linking provided by
